Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APX 005M

Drug Profile

APX 005M

Alternative Names: APX 005; APX 005M; EPI-0050

Latest Information Update: 14 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Epitomics
  • Developer Apexigen; Bristol-Myers Squibb; Parker Institute for Cancer Immunotherapy; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; Yale University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoprotein stimulants; Apoptosis stimulants; CD40 antigen stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Malignant melanoma; Oesophageal cancer; Pancreatic cancer; Soft tissue sarcoma
  • Phase I/II Non-small cell lung cancer
  • Phase I Brain cancer; Glioma; Renal cell carcinoma
  • No development reported Solid tumours

Most Recent Events

  • 18 Oct 2019 Apexigen and University of Texas Southwestern Medical Center plan a phase III trial for Rectal cancer (First-line therapy, Late-stage disease, Neoadjuvant therapy) in USA (IV) in November 2019 (NCT04130854)
  • 25 Sep 2019 Adverse events and efficacy data from a phase-I/II trial in Malignant melanoma presented at the 5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR-2019)
  • 01 Apr 2019 Efficacy and adverse events data from a phase Ib/II trial in Malignant melanoma released by Apexigen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top